A Chinese scientist reviewing laboratory equipment

Research news

This section contains news items that were not issued as a press release.

Monday, 11 May 2015
Mene Pangalos elected to the Fellowship of the Academy of Medical Sciences IMED leader one of 48 new fellows recognised for the advancement of medical science in the UK
Tuesday, 21 April 2015
AstraZeneca and Bina collaborate to deploy genomic management solution in R&D AstraZeneca and Bina Technologies, Inc., a member of the Roche Group, today announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Programme and to further develop the Bina Genomic Management Solution (GMS) . AstraZeneca will utilise the Bina GMS to support its development work across its main therapeutic areas of respiratory, inflammation and autoimmunity, cardiovascular and metabolic disease, and oncology.
Thursday, 19 March 2015
AstraZeneca establishes Scientific Review Board to support clinical trial data transparency commitment AstraZeneca today announced the creation of an independent Scientific Review Board to assess requests from external researchers which include patient level data.
Wednesday, 11 March 2015
AstraZeneca to collaborate with key Singapore research organisations in heart failure AstraZeneca today announced a two year collaboration with leading organisations in Singapore, including the Agency for Science, Technology and Research (A*STAR), National University Heart Centre, Singapore (NUHCS) and National University of Singapore, to support research into new therapies for heart failure. In particular, the collaboration will aim to advance understanding of the pathophysiology of heart failure with preserved ejection fraction (HFpEF), a complex syndrome, for which there is currently no effective treatment for patients.
Thursday, 26 February 2015
AstraZeneca to create stand-alone company for small molecule early-stage antibiotic R&D In line with AstraZeneca’s strategy to sharpen its focus on three main therapy areas, the company is changing the structure of its small molecule early-stage anti-infectives research and development.
Wednesday, 25 February 2015
AstraZeneca and Orca Pharmaceuticals announce research collaboration to identify best-in-class RORγ inhibitors to treat auto-immune diseases AstraZeneca and Orca Pharmaceuticals, a UK based biopharmaceutical company, today announced a three year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma (ROR). Inhibitors of this receptor are believed to have potential against a wide range of autoimmune diseases for which there is currently no safe, effective oral treatment.
Friday, 28 November 2014
AstraZeneca to collaborate with Cancer Research UK in screening for new cancer medicines at the AstraZeneca MRC UK Centre for Lead Discovery AstraZeneca and Cancer Research UK today announced that they have signed a memorandum of understanding through which Cancer Research UK drug discovery investigators would be given access to state-of-the-art drug discovery facilities at the new AstraZeneca MRC UK Centre for Lead Discovery to be built in Cambridge.
Thursday, 13 November 2014
AstraZeneca and Isis Pharmaceuticals to co-develop targeted oligonucleotide delivery methods AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively.
Tuesday, 23 September 2014
MedImmune receives fast track designation from FDA for development of MEDI3902  for prevention of nosocomial pneumonia AstraZeneca announced today that its global biologics research and development arm, MedImmune, has received fast track designation from the US Food and Drug Administration (FDA) for its investigational monoclonal antibody (mAb) MEDI3902 for the prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa (P. aeruginosa)
Wednesday, 3 September 2014
AstraZeneca and Redx Pharma agree research collaboration targeting genetic drivers of tumour growth AstraZeneca today announced that it has entered into a research collaboration with Redx Pharma Limited to discover and develop new molecules targeting a genetic driver of tumour growth and survival.